NEW YORK, March 6, 2014 /PRNewswire/ --
Editor Note: For more information about this release, please
scroll to bottom.
Today, Analysts Review released its analysts' notes regarding
Rockwood Holdings, Inc. (NYSE: ROC), Methanex Corp. (NASDAQ: MEOH),
Albemarle Corp. (NYSE: ALB), PolyOne Corporation (NYSE: POL), and
Amyris, Inc. (NASDAQ: AMRS). Private wealth members receive these
notes ahead of publication. To reserve complementary membership,
limited openings are available at:
http://www.AnalystsReview.com/register
--
Rockwood Holdings, Inc. Analyst Notes
On February 18, 2014, Rockwood
Holdings, Inc. (Rockwood) announced that its Board of Directors has
declared a quarterly cash dividend in the amount of $0.45 per share. The Company informed that the
dividend is payable on March 18, 2014
to all common stockholders of record at the close of business on
March 3, 2014. The full analyst notes
on Rockwood Holdings, Inc. are available to download free of charge
at:
http://www.AnalystsReview.com/03062014/ROC/report.pdf
--
Methanex Corp. Analyst Notes
On February 27, 2014, Methanex
Corp.'s (Methanex) stock increased 3.26% to end the day at
$69.37, compared to the previous
day's closing price of $67.18. The
Company's stock rose 6.97% over the past three trading days,
compared to the Nasdaq Composite which gained 0.60% during the same
trading period. The full analyst notes on Methanex Corp. are
available to download free of charge at:
http://www.AnalystsReview.com/03062014/MEOH/report.pdf
--
Albemarle Corp. Analyst Notes
On February 25, 2014, Albemarle
Corp. (Albemarle) reported that its Board of Directors has
announced a quarterly dividend of c.$0.28 per share, representing an increase of
c.15% over the previous quarterly dividend of $0.24. The Company stated that the dividend is
payable on April 1, 2014 to
shareholders of record at the close of business on March 14, 2014. Albemarle added that the new
annualized rate is $1.10. According
to the Company, this announcement marks the 20th
consecutive year of dividend increases. President and CEO
Luke Kissam, commented, "We are
proud of our long history of dividend growth and expect future
financial performance to allow this trend to continue." The full
analyst notes on Albemarle Corp. are available to download free of
charge at:
http://www.AnalystsReview.com/03062014/ALB/report.pdf
--
PolyOne Corporation Analyst Notes
On February 10, 2014, PolyOne
Corp. (PolyOne) announced the addition of new capabilities to its
OnColor™ HC Plus portfolio. According to the Company, these
expanded offerings add medical-grade LDPE, nylon, PEBA, PS and PVC
to the globally available palette of specialty healthcare
colorants, and are pre-certified to meet or exceed biocompatibility
requirements for ISO 10993 and/or USP Class VI protocols.
James Petrie, Marketing Director for
PolyOne Color and Additives, said, "This expansion of the OnColor
HC Plus portfolio reinforces our commitment to the healthcare
industry and adds new alternatives for customers who seek to
streamline their qualification, testing and supply chain management
processes." The full analyst notes on PolyOne Corporation are
available to download free of charge at:
http://www.AnalystsReview.com/03062014/POL/report.pdf
--
Amyris, Inc. Analyst Notes
On February 25, 2014, Amyris, inc.
(Amyris) and International flavors & Fragrances Inc. (IFF)
announced the completion of the first phase of their collaboration
in developing a specific set of renewable fragrance ingredients.
Amyris stated that both companies have reached an agreement to move
forward with the second phase of development. Commenting on the
partnership, John Melo, Amyris
President and CEO, commented, "We are extremely pleased with the
success in our collaboration with IFF and are optimistic about the
prospect for scaling up new fragrance compounds using our
technology platform." The Company informed that under the terms of
the multi-year agreement, IFF will have exclusive rights to the
renewable fragrance ingredients developed for applications in the
flavors and fragrances sector, and Amyris will have exclusive
rights in other sectors." The full analyst notes on Amyris, Inc.
are available to download free of charge at:
http://www.AnalystsReview.com/03062014/AMRS/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Analysts Review